Trial Profile
A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Cyclophosphamide; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 19 Jan 2024 Status changed from active, no longer recruiting to completed.
- 20 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 24 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.